|

Neoantigen-based peptide vaccine Clinical Trials

4 actively recruiting trials

Pipeline

Phase 2: 1

Top Sponsors

  • The First Affiliated Hospital of Nanchang University4

Indications

  • Cancer4
  • Advanced NSCLC2
  • Colorectal Cancer (CRC)2

Other4 trials

Neoantigen-based Peptide Vaccine and Conventional Second-line Therapy for CRC Progressed After First-line Treatment
N/A
Neoantigen-based Peptide Vaccine and Conventional Third-line Therapy for CRC Progressed After Second-line Treatment
N/A
Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment
N/A
Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.